Shares in vaccine maker Moderna (NASDAQ:MRNA) more than doubled overnight to $174 on positive trial data for one of its cancer drugs. The treatment, developed jointly with Merck (NYSE:MRK), met its endpoints in Phase 3 trials under the INTerpath clinical development programme. Shares more than double on drug’s prospects Investors piled into Moderna shares, sending … Continue reading Why Moderna shares more than doubled overnight